Adam S. Grossman

President and Chief Executive Officer (CEO) at ADMA BIOLOGICS

Board

Since October 2011

Age

47 years

Education

Earned a B.S. in Business Administration with a specialization in International Business and Marketing from American University.

Tenure

Became a director in 2007, served as President and Chief Operating Officer until October 2011, and has been President and Chief Executive Officer since then, with an additional role as Interim CFO since April 2024.

Also at ADMA BIOLOGICS

Kaitlin Kestenberg

Chief Operating Officer and Senior Vice President, Compliance

About

Adam S. Grossman is the President and Chief Executive Officer of ADMA, having joined the company as a director in 2007 and advancing through successive leadership roles. He served as President and Chief Operating Officer until his promotion to CEO in October 2011, and later assumed the Interim CFO role in April 2024.

With over 25 years of experience in the blood and plasma industry, his career encompasses significant expertise in launching products, managing clinical trials, and executing business development transactions. His professional journey includes pivotal roles at National Hospital Specialties, GenesisBPS, MedImmune, and the American Red Cross.

On a personal note, he is closely connected to ADMA through his family, being the son of Dr. Jerrold B. Grossman, a co-founder and Vice Chairman of the company. This background, coupled with a solid educational foundation from American University, has contributed to his comprehensive approach to leadership in the healthcare sector.

$ADMA Performance Under Adam S. Grossman

Past Roles

Organization	Role	Date Range	Details
ADMA	Interim Chief Financial Officer	Since April 2024	Held prior to becoming CEO
ADMA	President and Chief Operating Officer	2007 - October 2011	Held before becoming CEO
GenesisBPS	Executive Vice President of National Hospital Specialties	1994 - 2011	Launched new products, built/managing national and international sales forces, managed clinical trials, and executed business development transactions
MedImmune, Inc.	Marketing Team Member (RSV and CMV immunoglobulins)	N/A	Worked on marketing teams for RSV and CMV immunoglobulins
American Red Cross	Role in Biomedical Services Division	N/A	Launched new products with the Biomedical Services division

External Roles

Organization	Role	Date Range	Details
Plasma Protein Therapeutics Association	Chair of the North America Board of Directors	Since September 2023	N/A

Fixed Compensation

Data from FY 2025

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$925,000	Annual	Approved base salary for 2025
RSUs	252,022 RSUs	Vest quarterly over 4 years	Grant Date: February 19, 2025; awarded under the ADMA Biologics, Inc. 2022 Equity Compensation Plan
Stock Options	376,744 shares at $16.07 per share	Vest 25% on one-year anniversary; remaining 75% vest monthly over next 3 years, fully vested on February 19, 2029	Grant Date: February 19, 2025; reflects fair market value

Performance Compensation

Data from FY 2025

No information available on performance compensation for 2025